Becton Dickinson & Co.: Device Recall

Recall #Z-0621-2025 · 11/06/2024

Class II: Risk

Recall Details

Recall Number
Z-0621-2025
Classification
Class II
Product Type
Device
Recalling Firm
Becton Dickinson & Co.
Status
Ongoing
Date Initiated
11/06/2024
Location
Sparks, MD, United States
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
13,190 units

Reason for Recall

BD identified through potency testing as part of a stability test request to monitor Ampicillin AM-2 due to decrease in potency results of 65% at 18 months, may result in falsely resistant result for ampicillin susceptibility

Product Description

BD BBL Sensi Disc Ampicillin 2 ¿g (AM-2) - In-Vitro BD BBL Sensi Disc Ampicillin 2 ¿g (AM-2) are used for semi-quantitative in vitro susceptibility testing by the agar disc diffusion test procedure of common, rapidly growing and certain fastidious bacterial pathogens. Catalog Number: 231263

Distribution Pattern

Worldwide - US Nationwide distribution in the states of CA, GA, IL, KY, MA, MD, NE, PA and the countries of Canada, Belgium, Singapore, Malaysia.

Other Recalls by Becton Dickinson & Co.

View all recalls by Becton Dickinson & Co. →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.